SWOG S1802

Clinical Trial Title Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer)
Trial Status Closed to Enrollment
Start Date 09/17/2018
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Prostate cencer
Description This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Eligibility Criteria

Eligibility Criteria

  • All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
  • Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed
  • Patients must have technetium bone scan, and either CT of abdomen & pelvis or a MRI of pelvis within 42 days prior to starting standard systemic therapy, with evidence of metastatic disease on at least one scan.
  • Patients with known brain metastases are not eligible.
  • Patients must have received no more than 28 weeks of SST.
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated Stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

 
IRB Number Central IRB
Notes https://clinicaltrials.gov/ct2/show/NCT03678025?term=swog+s1802
Principal Investigator Jacqueline Vuky, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org